Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)

COVID-19 Clinical Trial

Official title:

A Randomized, Double-blind, Placebo Controlled Phase II / III Study to Assess Safety, Immunogenicity and Efficacy of Twice Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04655625
• Other study ID #: AG0302-COVID19-JN-02
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: November 23, 2020
• Est. completion date: February 1, 2022

Study information

• Verified date: June 2022
• Source: AnGes, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will assess the safety, immunogenicity and efficacy of AG0302-COVID19 in healthy adult volunteers.

Description:

This is a Phase II /III, multi-center, randomized, double-blind, placebo controlled trial. Approximately 500 healthy volunteers, male or female, aged 18 years or older, will be randomized to one of the following two groups:

Group A: Vaccination twice at 2-week intervals (n = 250) Group B: Vaccination twice at 4-week intervals (n = 250)

Fifty subjects in each group will receive placebos.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 500
• Est. completion date: February 1, 2022
• Est. primary completion date: April 2, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects who have obtained written consent voluntarily to participate in this clinical trial

2. Subjects whose age at the time of obtaining consent is 18 years or older

3. Subjects who are negative for SARS-CoV-2 by PCR test

4. Subjects who are negative for both SARS-CoV-2 IgM antibody and SARS-CoV-2 IgG antibody by antibody test

Exclusion Criteria:

1. Subjects with symptoms of suspected COVID-19 infection (respiratory symptoms, headache, malaise, olfactory disorders, taste disorders, etc.)

2. Subjects with a history of COVID-19 (hearing from subjects)

3. Subjects who have participated in unapproved vaccine clinical trials within 1 year before the start of this study

4. Subjects with axillary temperature of 37.0 degree or higher at the time of screening and before the first vaccination

5. Subjects who have a history of anaphylaxis

6. Subjects who have a history of hypersensitivity to the ingredients of the investigational drug

7. Subjects who have a current or history of serious renal, cardiovascular, respiratory, liver, kidney, gastrointestinal, and neuropsychiatric diseases

8. Subjects with a history of convulsion or epilepsy

9. Subjects with a history of diagnosis of immunodeficiency

10. Subjects who have a close relative (within 3rd degree) of congenital immunodeficiency

11. Subjects who have current bronchial asthma

12. Subjects who have had a fever of 39.0 degrees or higher within 2 days after vaccination, or who have been suspected of having an allergy such as a systemic rash.

13. Females who wish to become pregnant from the study registration to 12 weeks after the first vaccination, and pregnant females who are breast-feeding. In addition, females who may become pregnant and their male sexual partners should use appropriate contraceptives (pill), condoms, vasectomy, tubal ligation, diaphragm, intrauterine devices, spermicides, intrauterine hormone-releasing system, etc. from the study entry date until 12 weeks after the first vaccination

14. Subjects who have participated in clinical trials of other unapproved drugs and received the investigational drug within 4 weeks before the start of this clinical trial (starting from vaccination day)

15. Subjects who have been received a live vaccine, inactivated vaccine, or toxoid within 4 weeks before the start of this clinical trial (starting from vaccination day)

16. Subjects who have been administered with drugs that affect the immune system (excluding external preparations) such as immunomodulators (DMARDs, etc.), immunosuppressants, biologics, etc. within 4 weeks before vaccination

17. Subjects who received blood transfusion or gamma globulin therapy within 12 weeks before vaccination, or high-dose gamma globulin therapy (200 mg/kg or more) within 24 weeks before vaccination

18. Subjects who have a history of overseas travel within 4 weeks before the start of the clinical trial (starting from vaccination day)

19. Subjects who are unable to comply with the clinical trial protocol and follow up (for mental, family, social or geographical reasons)

20. Subjects who are judged to be ineligible for this clinical trial by the investigator

Related Conditions & MeSH terms

• COVID-19

Intervention

Biological:
• Group A (AG0302-COVID19)
2 mg of AG0302-COVID19 twice at 2-week intervals
• Group A (Placebo)
Placebo twice at 2-week intervals
• Group B (AG0302-COVID19)
2 mg of AG0302-COVID19 twice at 4-week intervals
• Group B (Placebo)
Placebo twice at 4-week intervals

Locations

Country	Name	City	State
Japan	UHW Narita Hospital	Narita	Chiba
Japan	Medical Corporation Heishinkai OPHAC Hospital	Osaka
Japan	NISHI-UMEDA Clinic for Asian Medical Collaboration	Osaka
Japan	Medical Corporation Tsurukamekai Shinjuku Tsurukame C linic	Shibuya-ku	Tokyo
Japan	Medical Corporation Heishinkai ToCROM Clinic	Shinjuku-ku	Tokyo
Japan	Medical Corporation Shinanokai Shinanozaka Clinic	Shinjuku-ku	Tokyo
Japan	Medical Corporation Heishinkai OCROM Clinic	Suita	Osaka
Japan	Sekino Clinical Pharmacology Clinic	Toshima-ku	Tokyo

Sponsors (2)

Lead Sponsor	Collaborator
AnGes, Inc.	Japan Agency for Medical Research and Development

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment-Emergent Adverse Events	Frequency and severity of each adverse event solicited local and systemic AEs from the first vaccination to 4 weeks after the second vaccination	Group A: 6 weeks Group B: 8 weeks
Primary	Immunogenicity	Change in Geometric mean titer (GMT) of serum anti-SARS-CoV-2 Spike (S) glycoprotein-specific antibody	Group A: Week 7 Group B: Week 9
Secondary	Change in GMT of anti-SARS-CoV-2 Spike (S) glycoprotein-specific antibody		Group A: Weeks 5, 25, 53 Group B: Weeks 7, 25, 53
Secondary	Change in the neutralizing activity against pseudovirus of SARS-CoV-2		Group A: Weeks 5, 7, 25, 53 Group B: Weeks 7, 9, 25, 53
Secondary	Change in IFN-gamma production against SARS-CoV-2 spike (S) glycoprotein by T cells in peripheral blood mononuclear cells		Group A: Weeks 5, 7, 25, 53 Group B: Weeks 7, 9, 25, 53
Secondary	IgG subclasses (IgG1 and IgG2) of anti-SARS-CoV-2 spike (S) glycoprotein-specific antibody		Group A: Weeks 5, 7, 25, 53 Group B: Weeks 7, 9, 25, 53
Secondary	Adverse events		Group A: Week 7 through Week 53 Group B: Week 9 through Week 53
Secondary	Rate of SARS-CoV-2 positive and incidence rate of COVID-19 after the first vaccination		Week 1 through Week 53